mast image

Special Report

Impact investing

Sections

PKA joins biggest European biotech cash injection

Related images

  • PKA joins biggest European biotech cash injection

Related Categories

DENMARK - PKA has announced it is investing around DKK140m (€19m) in a Danish biotech firm developing cancer drugs, part of what it says is the biggest capital injection ever into a European biotech business.

The Danish pension fund group said its investment of DKK140m is part of a DKK750m injection into the biotech company Symphogen.

Other investors include Novo A/S and Essex Woodlands Fund VIII of the US. The capital is being raised by private placement of preferred stock.

Symphogen is a private biopharmaceutical company developing antibody therapeutics to treat cancer and infectious and autoimmune diseases.

The biotech firm said it intends to use the money raised to speed up the progress on its main clinical oncology product Sym004, as well as moving forward with other anti-cancer projects.

Michael Nelleman Pedersen, investment director at PKA, said the pensions administration group had big hopes for Symphogen.

"Symphogen has attracted international attention with its prospects of taking cancer research a step further, and we are confident that the business can develop and market its products further for cancer treatments and other diseases," he said.

"We believe the business will be able to give our members' pensions a good return; over and above this, our members, many of whom work in the health sector, will certainly approve of PKA investing in a business which is researching into finding a treatment for cancer," Nelleman Pedersen said.

PKA is the joint administration group for eight Danish pension funds, and managed total assets of DKK122bn at the end of 2009.

Have your say

You must sign in to make a comment

IPE QUEST

Your first step in manager selection...

IPE Quest is a manager search facility that connects institutional investors and asset managers.

  • QN-2548

    Asset class: Fixed Income, Emerging Market Debt Hard Currency (Active).
    Asset region: Emerging Markets.
    Size: CHF 300-400m.
    Closing date: 2019-07-30.

  • QN-2549

    Asset class: Fixed Income, Emerging Market Debt Hard Currency (Passive or Passive Enhanced).
    Asset region: Emerging Markets.
    Size: CHF 300-700m.
    Closing date: 2019-07-30.

  • QN-2550

    Asset class: Fixed Income, Emerging Market Debt Local Currency (Active).
    Asset region: Emerging Markets.
    Size: CHF 250-350m.
    Closing date: 2019-07-31.

  • QN-2551

    Asset class: Fixed Income, Emerging Market Debt Local Currency (Passive or Passive Enhanced).
    Asset region: Emerging Markets.
    Size: CHF 250-350m.
    Closing date: 2019-07-31.

  • QN-2552

    Asset class: Fixed Income, High Yield (Active).
    Asset region: High Yield (US).
    Size: CHF 500-600m.
    Closing date: 2019-07-29.

  • QN-2553

    Asset class: Fixed Income, High Yield (Passive or Passive Enhanced).
    Asset region: High Yield (US).
    Size: CHF 500-1'100m.
    Closing date: 2019-07-29.

  • QN-2554

    Asset class: Global Real Estate (Equity, unlisted Funds).
    Asset region: World (ex-Switzerland).
    Size: CHF 200 mn (potential for further growth).
    Closing date: 2019-08-07.

  • QN-2555

    Asset class: Real Estate.
    Asset region: European.
    Size: EUR 50 - 100 million.
    Closing date: 2019-07-22.

  • QN-2556

    Asset class: FX Hedging.
    Asset region: Global.
    Size: Mandate size of CHF 1.5 bn.
    Closing date: 2019-08-09.

  • QN-2557

    Asset class: All/large Cap Equities.
    Asset region: China A-shares.
    Size: Unit linked platform (0m USD in initial investment).
    Closing date: 2019-08-01.

Begin Your Search Here
<